DZ2407A1 - Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant - Google Patents
Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenantInfo
- Publication number
- DZ2407A1 DZ2407A1 DZ980017A DZ980017A DZ2407A1 DZ 2407 A1 DZ2407 A1 DZ 2407A1 DZ 980017 A DZ980017 A DZ 980017A DZ 980017 A DZ980017 A DZ 980017A DZ 2407 A1 DZ2407 A1 DZ 2407A1
- Authority
- DZ
- Algeria
- Prior art keywords
- preparation
- pharmaceutical compositions
- compositions containing
- sulfonylurea derivatives
- derivatives process
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3697997P | 1997-01-29 | 1997-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
DZ2407A1 true DZ2407A1 (fr) | 2003-01-04 |
Family
ID=21891776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DZ980017A DZ2407A1 (fr) | 1997-01-29 | 1998-01-27 | Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant |
Country Status (40)
Country | Link |
---|---|
US (2) | US6166064A (es) |
EP (1) | EP0964849B1 (es) |
JP (1) | JP3573757B2 (es) |
KR (1) | KR100324058B1 (es) |
CN (1) | CN1127479C (es) |
AP (1) | AP929A (es) |
AR (1) | AR011093A1 (es) |
AT (2) | ATE270285T1 (es) |
AU (1) | AU723895B2 (es) |
BG (1) | BG103597A (es) |
BR (1) | BR9714328A (es) |
CA (1) | CA2279186C (es) |
CO (1) | CO4920230A1 (es) |
CZ (1) | CZ293173B6 (es) |
DE (2) | DE69729762T2 (es) |
DK (2) | DK0964849T3 (es) |
DZ (1) | DZ2407A1 (es) |
EA (1) | EA001803B1 (es) |
ES (2) | ES2222426T3 (es) |
HR (1) | HRP980045B1 (es) |
HU (1) | HUP0000567A3 (es) |
ID (1) | ID22223A (es) |
IL (1) | IL130855A0 (es) |
IS (1) | IS5099A (es) |
MA (1) | MA26468A1 (es) |
NO (1) | NO313279B1 (es) |
NZ (1) | NZ336248A (es) |
OA (1) | OA11079A (es) |
PA (1) | PA8444701A1 (es) |
PE (1) | PE57898A1 (es) |
PL (1) | PL335052A1 (es) |
PT (2) | PT964849E (es) |
SK (1) | SK283679B6 (es) |
TN (1) | TNSN98017A1 (es) |
TR (1) | TR199901816T2 (es) |
TW (1) | TW515788B (es) |
UY (1) | UY24861A1 (es) |
WO (1) | WO1998032733A1 (es) |
YU (1) | YU33799A (es) |
ZA (1) | ZA98685B (es) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022984A (en) * | 1998-07-27 | 2000-02-08 | Pfizer Inc. | Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors |
EP1526383A3 (en) * | 1998-08-31 | 2005-11-16 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
IT1303249B1 (it) * | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
WO2001019390A1 (en) * | 1999-09-14 | 2001-03-22 | Pfizer Products Inc. | Combination treatment with il-1ra and diaryl sulphonyl urea compounds |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
EP2087908B1 (en) | 2001-06-26 | 2018-05-30 | Amgen Inc. | Antibodies to opgl |
CA2459454A1 (en) | 2001-09-14 | 2003-03-27 | Bayer Pharmaceuticals Corporation | Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists |
EP1487457A1 (en) * | 2001-11-30 | 2004-12-22 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
US20030131370A1 (en) * | 2001-12-14 | 2003-07-10 | Pfizer Inc. | Disruption of the glutathione S-transferase-Omega-1 gene |
ATE349210T1 (de) | 2002-07-09 | 2007-01-15 | Boehringer Ingelheim Pharma | Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege |
CA2497884C (en) | 2002-09-06 | 2013-10-22 | Brian Varnum | Therapeutic human anti-il-1r1 monoclonal antibody |
WO2004031777A1 (en) * | 2002-10-03 | 2004-04-15 | Pfizer Products Inc. | Use of gst-omega-2 as a therapeutic target |
BRPI0413347A (pt) | 2003-08-06 | 2006-10-10 | Senomyx Inc | novos sabores, modificadores de sabor, agentes de sabor, realçadores de sabor, agentes de sabor e/ou realçadores umami ou doces, e utilização correspondente |
RU2375347C2 (ru) * | 2004-03-23 | 2009-12-10 | Домпе С.П.А. | Производные 2-фенилпропионовой кислоты и содержащие их фармацевтические композиции |
US20060045953A1 (en) * | 2004-08-06 | 2006-03-02 | Catherine Tachdjian | Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
JP4734346B2 (ja) | 2005-02-04 | 2011-07-27 | セノミックス インコーポレイテッド | 連結ヘテロアリール部分を含む化合物、ならびに食用組成物のための新規なうまみフレーバー改変剤、味物質および味覚増強剤としての使用 |
WO2006090932A1 (ja) * | 2005-02-28 | 2006-08-31 | Eisai R & D Managemant Co., Ltd. | スルホンアミド化合物の代理マーカー |
US7208526B2 (en) * | 2005-05-20 | 2007-04-24 | Hoffmann-La Roche Inc. | Styrylsulfonamides |
AR055329A1 (es) | 2005-06-15 | 2007-08-15 | Senomyx Inc | Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor |
EP3398452A3 (en) | 2006-04-21 | 2018-11-28 | Senomyx, Inc. | Comestible compositions comprising high potency savory flavorants, and processes for producing them |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
US7973051B2 (en) * | 2007-11-30 | 2011-07-05 | Hoffman-La Roche Inc. | Aminothiazoles as FBPase inhibitors for diabetes |
EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA |
WO2016025637A1 (en) | 2014-08-12 | 2016-02-18 | Loyola University Of Chicago | Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same |
MX2017010528A (es) * | 2015-02-16 | 2018-11-12 | Univ Queensland | Sulfonilureas y compuestos relacionados y uso de estos. |
US10688077B2 (en) * | 2015-02-26 | 2020-06-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inflammasome activation in myelodysplastic syndromes |
FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
AU2017219204A1 (en) * | 2016-02-16 | 2018-08-23 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Sulfonylureas and related compounds and use of same |
ES2940611T3 (es) * | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
WO2017184623A1 (en) * | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
EP3272739A1 (en) * | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
WO2018102419A1 (en) * | 2016-11-29 | 2018-06-07 | Epizyme, Inc. | Compounds containing a sulfonic group as kat inhibitors |
UA126675C2 (uk) | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
BR112019024831A2 (pt) | 2017-05-24 | 2020-06-09 | The University Of Queensland | composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3 |
WO2018225018A1 (en) | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
JP7235742B2 (ja) | 2017-07-07 | 2023-03-08 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
IL271259B2 (en) | 2017-07-24 | 2024-06-01 | Novartis Inflammasome Res Inc | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RELATED TO NLRP ACTIVITY |
JP2020531453A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | Nlrp3阻害剤としてのスルホニルウレアおよびスルホニルチオウレア |
US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
AU2018317800A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
WO2019034697A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
EP3692020A1 (en) | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
CN111417622A (zh) | 2017-10-17 | 2020-07-14 | 诺华炎症研究公司 | 用于治疗与nlrp活性相关的病症的磺胺类及其组合物 |
SG11202003984UA (en) | 2017-11-09 | 2020-05-28 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
CN108299256B (zh) * | 2018-01-09 | 2019-09-10 | 武汉大学 | 一类2,3,4-三羟基苯磺酰胺衍生物及其制备方法和应用 |
EP3759103A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
US12030879B2 (en) | 2018-03-02 | 2024-07-09 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
EP3759102A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
WO2019166628A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
WO2020010143A1 (en) | 2018-07-03 | 2020-01-09 | Novartis Inflammasome Research, Inc. | Nlrp modulators |
EP3823726A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche SA | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
JP2022505525A (ja) | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Nlrp活性に関連する状態を治療するための化合物及び組成物 |
MX2021008426A (es) | 2019-01-14 | 2021-09-23 | Cadila Healthcare Ltd | Nuevos derivados de sulfonilurea sustituida. |
US20220378801A1 (en) | 2019-06-21 | 2022-12-01 | Ac Immune Sa | Novel compounds |
US20220313657A1 (en) * | 2019-09-12 | 2022-10-06 | Cadila Healthcare Limited | Novel substituted sulfoximine derivatives |
JP7504234B2 (ja) * | 2020-06-11 | 2024-06-21 | シーセン ファーマシューティカル カンパニー リミテッド | ジメチルスルホキシミン誘導体 |
CN115768754A (zh) | 2020-06-19 | 2023-03-07 | Ac免疫有限公司 | 调节nlrp3炎症小体通路的二氢噁唑和硫脲或脲衍生物 |
WO2022022646A1 (zh) * | 2020-07-29 | 2022-02-03 | 南京明德新药研发有限公司 | 含硒五元杂芳环化合物 |
CN116783184A (zh) | 2020-09-04 | 2023-09-19 | 诺瑟拉有限公司 | 含有烷基-氧杂环烷基部分的氨磺酰基脲衍生物及其用途 |
ES2948511A1 (es) * | 2021-09-08 | 2023-09-13 | Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa | Derivados de n-sulfonilureas y su uso terapeutico |
WO2023098612A1 (zh) * | 2021-12-03 | 2023-06-08 | 南京明德新药研发有限公司 | 二甲基亚磺酰亚胺衍生物的盐型及晶型 |
WO2023118521A1 (en) | 2021-12-22 | 2023-06-29 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
WO2023156311A1 (en) * | 2022-02-15 | 2023-08-24 | F. Hoffmann-La Roche Ag | Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
US20240034735A1 (en) | 2022-07-14 | 2024-02-01 | Ac Immune Sa | Novel compounds |
US20240101563A1 (en) | 2022-07-28 | 2024-03-28 | Ac Immune Sa | Novel compounds |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4586950A (en) * | 1982-05-31 | 1986-05-06 | E. I. Du Pont De Nemours & Company | Novel phenyl-substituted sulfonamides |
US4780125A (en) * | 1982-09-01 | 1988-10-25 | Ciba-Geigy Corporation | N-phenylsulfonyl-N'-triazinylureas |
DE3927369A1 (de) * | 1989-08-19 | 1991-02-21 | Bayer Ag | Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe |
US5064851A (en) * | 1990-07-24 | 1991-11-12 | Pfizer Inc. | 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use |
US5254589A (en) * | 1991-10-15 | 1993-10-19 | Warner-Lambert Company | Sulfonyl urea and carbamate ACAT inhibitors |
DE4344957A1 (de) * | 1993-12-30 | 1995-07-06 | Hoechst Ag | Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen |
CN1038679C (zh) * | 1994-12-07 | 1998-06-10 | 南开大学 | 磺酰脲类化合物及其除草用途 |
HU226462B1 (en) * | 1995-02-17 | 2008-12-29 | Hoechst Ag | Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use |
AU6967198A (en) * | 1997-04-10 | 1998-10-30 | Eli Lilly And Company | Diarylsulfonylureas for use in treating secretory diarrhea |
-
1997
- 1997-12-29 PT PT97947201T patent/PT964849E/pt unknown
- 1997-12-29 IL IL13085597A patent/IL130855A0/xx unknown
- 1997-12-29 ES ES02020749T patent/ES2222426T3/es not_active Expired - Lifetime
- 1997-12-29 PT PT02020749T patent/PT1270565E/pt unknown
- 1997-12-29 US US09/341,782 patent/US6166064A/en not_active Expired - Fee Related
- 1997-12-29 NZ NZ336248A patent/NZ336248A/xx unknown
- 1997-12-29 AU AU52340/98A patent/AU723895B2/en not_active Ceased
- 1997-12-29 JP JP51868798A patent/JP3573757B2/ja not_active Expired - Fee Related
- 1997-12-29 PL PL97335052A patent/PL335052A1/xx unknown
- 1997-12-29 SK SK982-99A patent/SK283679B6/sk unknown
- 1997-12-29 KR KR1019997006786A patent/KR100324058B1/ko not_active IP Right Cessation
- 1997-12-29 HU HU0000567A patent/HUP0000567A3/hu unknown
- 1997-12-29 ID IDW990764A patent/ID22223A/id unknown
- 1997-12-29 DE DE69729762T patent/DE69729762T2/de not_active Expired - Fee Related
- 1997-12-29 AT AT02020749T patent/ATE270285T1/de not_active IP Right Cessation
- 1997-12-29 BR BR9714328A patent/BR9714328A/pt not_active Application Discontinuation
- 1997-12-29 AT AT97947201T patent/ATE242208T1/de not_active IP Right Cessation
- 1997-12-29 DE DE69722663T patent/DE69722663T2/de not_active Expired - Fee Related
- 1997-12-29 TR TR1999/01816T patent/TR199901816T2/xx unknown
- 1997-12-29 ES ES97947201T patent/ES2198598T3/es not_active Expired - Lifetime
- 1997-12-29 CZ CZ19992575A patent/CZ293173B6/cs not_active IP Right Cessation
- 1997-12-29 CN CN97181579A patent/CN1127479C/zh not_active Expired - Fee Related
- 1997-12-29 WO PCT/IB1997/001603 patent/WO1998032733A1/en active IP Right Grant
- 1997-12-29 CA CA002279186A patent/CA2279186C/en not_active Expired - Fee Related
- 1997-12-29 DK DK97947201T patent/DK0964849T3/da active
- 1997-12-29 EA EA199900603A patent/EA001803B1/ru not_active IP Right Cessation
- 1997-12-29 YU YU33799A patent/YU33799A/sh unknown
- 1997-12-29 DK DK02020749T patent/DK1270565T3/da active
- 1997-12-29 EP EP97947201A patent/EP0964849B1/en not_active Expired - Lifetime
-
1998
- 1998-01-16 PA PA19988444701A patent/PA8444701A1/es unknown
- 1998-01-20 UY UY24861A patent/UY24861A1/es unknown
- 1998-01-23 PE PE1998000051A patent/PE57898A1/es not_active Application Discontinuation
- 1998-01-26 TW TW087101087A patent/TW515788B/zh not_active IP Right Cessation
- 1998-01-27 DZ DZ980017A patent/DZ2407A1/xx active
- 1998-01-27 AR ARP980100358A patent/AR011093A1/es not_active Application Discontinuation
- 1998-01-27 HR HR980045A patent/HRP980045B1/xx not_active IP Right Cessation
- 1998-01-28 ZA ZA9800685A patent/ZA98685B/xx unknown
- 1998-01-28 MA MA24947A patent/MA26468A1/fr unknown
- 1998-01-28 TN TNTNSN98017A patent/TNSN98017A1/fr unknown
- 1998-01-29 AP APAP/P/1998/001190A patent/AP929A/en active
- 1998-01-29 CO CO98004326A patent/CO4920230A1/es unknown
-
1999
- 1999-06-29 IS IS5099A patent/IS5099A/is unknown
- 1999-07-22 BG BG103597A patent/BG103597A/bg unknown
- 1999-07-23 OA OA9900165A patent/OA11079A/en unknown
- 1999-07-28 NO NO19993658A patent/NO313279B1/no not_active IP Right Cessation
-
2000
- 2000-10-31 US US09/703,142 patent/US6433009B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DZ2407A1 (fr) | Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant | |
DZ2197A1 (fr) | Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2300A1 (fr) | Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2299A1 (fr) | Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2394A1 (fr) | Dérivés de quinoléine et dérivés de quinazoline nouveax procédé pour leur préparation et compositions pharmaceutiques les contenant | |
DZ2581A1 (fr) | Dérivés d'acides aryloxyarylsulfonylaminohydroxamiques procédé pour leur préparation et compositionspharmaceutiques les contenant. | |
CY2537B1 (fr) | Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant | |
DZ2303A1 (fr) | Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2758A1 (fr) | Dérivés bicycliques d0acide hydroxamique nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ1889A1 (fr) | Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2666A1 (fr) | Dérivés d'acide hydroxamique compositions pharmaceutiques les contenant et procédé pour leur préparation. | |
DZ2360A1 (fr) | Dérivés de pyrazole procédé pour leur préparation et compositions les contenant | |
DZ1957A1 (fr) | Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2773A1 (fr) | Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2550A1 (fr) | Dérivés d'azétidinylpropylpipéridine procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2777A1 (fr) | Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2745A1 (fr) | BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2414A1 (fr) | 2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2963A1 (fr) | Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2634A1 (fr) | Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant. | |
DZ2416A1 (fr) | Dérivés d'acide arylsulfonylhydroxamique procédé pour leur préparation et compositions les contenant. | |
MA26659A1 (fr) | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. | |
DZ2891A1 (fr) | Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2523A1 (fr) | Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation. | |
DZ2621A1 (fr) | AGonistes de prostaglandines nouveaux procédé pourleur préparation et compositions pharmaceutiques les contenant. |